Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$1.42
-$0.05(-3.57%)
At close: 4:00 PM EDT
$1.42
-$0.05(-3.57%)
Day’s Range― - ―
52-Week Range$1.20 - $4.44
Previous CloseN/A
Volume31.95K
Average Volume (3M)240.57K
Market Cap
$9.60M
Enterprise Value$26.66
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding7,384,073
10 Day Avg. Volume670,157
30 Day Avg. Volume240,568
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partner-funded VELDONA LicensingThe VELDONA structure can reduce Ainos’ future development funding burden while preserving platform ownership and potential royalty participation. Partner-funded clinical and regulatory execution also lets Ainos direct capital and management attention toward its Chemical Intelligence strategy.
AI Nose Commercial DeploymentInitial commercial orders provide evidence that AI Nose is moving beyond validation toward customer adoption in an industrial market. If deployment expands, this could diversify Ainos’ revenue base and create a repeatable commercialization path for its chemical-intelligence technology.
Expanding Intellectual PropertyThe newly granted patents broaden protection for AI Nose applications across rapid detection, gas exchange and robotics. A wider intellectual-property position may support differentiation, licensing opportunities and longer-term adoption as chemical sensing becomes part of physical AI systems.
Bears Say
Very Weak Operating PerformanceThe current revenue scale is far below the cost base, and recurring losses show that commercialization has not yet produced sustainable operating economics. Without materially stronger revenue or cost improvement, profitability and the ability to reinvest in growth remain constrained.
Persistent Cash BurnOngoing operating and free-cash-flow deficits mean Ainos must continue funding operations externally if the burn persists. This can restrict investment in product development and commercialization, while increasing dependence on financing or future licensing and order proceeds.
Shrinking Equity Cushion And LeverageThe sharp reduction in equity alongside higher leverage materially reduces financial flexibility. A smaller capital cushion leaves less capacity to absorb continued losses or fund expansion, and debt obligations may compete with strategic investment for available cash.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.20 and its highest was $4.44 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $9.60M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Nov 11, 2026 which is in 39 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Aug 03, 2026. The company reported -$0.624 earnings per share for the quarter.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 7,384,073 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.624 in its last earnings report. Following the earnings report the stock price went down -2.759%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
48.13% Insiders
0.43% Mutual Funds
0.37% Other Institutional Investors
50.85% Public Companies and
Individual Investors